Aeterna Zentaris reports Q4 EPS ($1.16) vs. ($2.56) last year

Reports revenue $0.1M vs. $2.5M last year. Klaus Paulini, Chief Executive Officer of Aeterna commented, “With enrollment now completed in the DETECT-trial, we expect the completion of the DETECT-trial in the second quarter and Top-Line Data in the third quarter of this year. In addition to achieving an important milestone for macimorelin in CGHD, we are also looking forward to closing the merger with Ceapro in the second quarter of 2024.”